| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative
|
Brouckaert, O.
|
|
|
24 |
1 |
p. 47-53
|
article
|
| 2 |
A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome
|
Soldini, D.
|
|
|
24 |
1 |
p. 193-201
|
article
|
| 3 |
An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas
†
|
Agulnik, M.
|
|
|
24 |
1 |
p. 257-263
|
article
|
| 4 |
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
|
Kaye, S.B.
|
|
|
24 |
1 |
p. 145-152
|
article
|
| 5 |
Breast cancer management and outcome according to surgeon's affiliation: a population-based comparison adjusted for patient's selection bias
|
Taban, F.
|
|
|
24 |
1 |
p. 116-125
|
article
|
| 6 |
Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis
|
Wen, F.
|
|
|
24 |
1 |
p. 171-178
|
article
|
| 7 |
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
|
Argiris, A.
|
|
|
24 |
1 |
p. 220-225
|
article
|
| 8 |
Chronic infection and other risk factors of cancer in China and other countries
|
Han-You, X.
|
|
|
24 |
1 |
p. 267
|
article
|
| 9 |
Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis
|
Xu, G.Z.
|
|
|
24 |
1 |
p. 96-101
|
article
|
| 10 |
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series
|
Fruscio, R.
|
|
|
24 |
1 |
p. 138-144
|
article
|
| 11 |
Controversies and challenges regarding the impact of radiation therapy on survival
|
Chargari, C.
|
|
|
24 |
1 |
p. 38-46
|
article
|
| 12 |
Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
|
Petrelli, F.
|
|
|
24 |
1 |
p. 186-192
|
article
|
| 13 |
Diagnostic and prognostic significance of the alternatively spliced ACTN4 variant in high-grade neuroendocrine pulmonary tumours
|
Miyanaga, A.
|
|
|
24 |
1 |
p. 84-90
|
article
|
| 14 |
Dietary glycemic load, glycemic index, and carbohydrates on the risk of primary liver cancer among Chinese women and men
|
Vogtmann, E.
|
|
|
24 |
1 |
p. 238-244
|
article
|
| 15 |
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis
|
Dieci, M.V.
|
|
|
24 |
1 |
p. 101-108
|
article
|
| 16 |
Editorial board
|
|
|
|
24 |
1 |
p. ii-iii
|
article
|
| 17 |
Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients
|
Ediebah, D.E.
|
|
|
24 |
1 |
p. 231-237
|
article
|
| 18 |
Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer
|
Weigel, M.T.
|
|
|
24 |
1 |
p. 126-133
|
article
|
| 19 |
Evidence-based role of bevacizumab in non-small cell lung cancer
|
Vokes, E.E.
|
|
|
24 |
1 |
p. 6-9
|
article
|
| 20 |
Fulvestrant and male breast cancer: a case series
|
Zagouri, F.
|
|
|
24 |
1 |
p. 265-266
|
article
|
| 21 |
Glycemic index, glycemic load and cancer risk
|
Hu, J.
|
|
|
24 |
1 |
p. 245-251
|
article
|
| 22 |
Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes
|
Wong, M.
|
|
|
24 |
1 |
p. 133-138
|
article
|
| 23 |
Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer
|
Hong, A.M.
|
|
|
24 |
1 |
p. 215-219
|
article
|
| 24 |
Influence of new late effects on quality of life over time in Hodgkin lymphoma Survivors: a longitudinal survey study
|
Khimani, N.
|
|
|
24 |
1 |
p. 226-230
|
article
|
| 25 |
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
†
|
Reck, M.
|
|
|
24 |
1 |
p. 75-83
|
article
|
| 26 |
Long-term survival among Hodgkin's lymphoma patients with gastrointestinal cancer: a population-based study
|
Youn, P.
|
|
|
24 |
1 |
p. 202-208
|
article
|
| 27 |
Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized controlled trial
|
Teoh, A.Y.B.
|
|
|
24 |
1 |
p. 165-171
|
article
|
| 28 |
Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer
|
Dorff, T.B.
|
|
|
24 |
1 |
p. 31-38
|
article
|
| 29 |
Meat consumption and risk of lung cancer: evidence from observational studies
|
Wang, F.
|
|
|
24 |
1 |
p. 266-267
|
article
|
| 30 |
Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study
|
Tiselius, C.
|
|
|
24 |
1 |
p. 160-165
|
article
|
| 31 |
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
|
Shaw, A.T.
|
|
|
24 |
1 |
p. 59-66
|
article
|
| 32 |
Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer
|
Besse, B.
|
|
|
24 |
1 |
p. 90-96
|
article
|
| 33 |
Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors
|
Dickson, M.A.
|
|
|
24 |
1 |
p. 252-257
|
article
|
| 34 |
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
|
Sorbye, H.
|
|
|
24 |
1 |
p. 152-160
|
article
|
| 35 |
Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx
|
Park, G.C.
|
|
|
24 |
1 |
p. 208-214
|
article
|
| 36 |
Risk factors for local and regional recurrence in patients with resected N0–N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy
|
Lopez Guerra, J.L.
|
|
|
24 |
1 |
p. 67-74
|
article
|
| 37 |
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
|
Awada, A.
|
|
|
24 |
1 |
p. 109-116
|
article
|
| 38 |
Seminars in clinical pharmacology: an introduction to MET inhibitors for the medical oncologist
|
Fasolo, A.
|
|
|
24 |
1 |
p. 14-20
|
article
|
| 39 |
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
|
Soria, J.-C.
|
|
|
24 |
1 |
p. 20-30
|
article
|
| 40 |
Table of Contents
|
|
|
|
24 |
1 |
p. iv-vi
|
article
|
| 41 |
thanks to referees 2012
|
|
|
|
24 |
1 |
p. 1-5
|
article
|
| 42 |
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial
|
Huijbers, A.
|
|
|
24 |
1 |
p. 179-185
|
article
|
| 43 |
Tolerability and activity of trastuzumab in elderly patients with HER2-overexpressing metastatic breast cancer
|
Zucchini, G.
|
|
|
24 |
1 |
p. 264-265
|
article
|
| 44 |
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines
|
|
|
|
24 |
1 |
p. 268
|
article
|
| 45 |
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
|
Inoue, A.
|
|
|
24 |
1 |
p. 54-59
|
article
|
| 46 |
Whole-body 18FDG–PET/CT or whole-body gadolinium-enhanced MRI for distant staging?
|
Bacigalupo, L.
|
|
|
24 |
1 |
p. 9-13
|
article
|
Journal description